Company intelligence / Profile preview

Seppic

Ownership: Private
Employees: ~770
Development stage: Commercial

Overview

Seppic develops and markets specialty excipients—including polymers and surfactants—for pharmaceutical formulations across oral, topical, and injectable routes. Their technologies enable improved stability, bioavailability, texture/sensory profile of finished drugs or vaccines. They also supply vaccine adjuvants. Products are widely used by pharma/biotech companies globally. No clinical results as they do not develop therapeutics directly.

Modalities: Excipients (for small molecules and biologics)Vaccine adjuvantsPolymers (as drug delivery systems)Surfactants (as formulation aids)Nanoparticle-based excipients (inferred from surfactant/polymers for injectables)
Industry: Chemicals & Materials

Partnerships

Not specified publicly; collaborates with global pharma/nutraceutical/cosmetic manufacturers as customers.

Beyond the preview

Go deeper on Seppic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seppic.

Explore the full profile